Hyaluronan and synovial joint: Function, distribution and healing

Interdisciplinary Toxicology

Volumn 6, Issue 3, 2013, Pages 111-125

  Tamer, Tamer Mahmoud ^a,b  

^a City of Scientific Research and Technological Applications ^*  (Egypt)

^b INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

Author keywords

antioxidant; hyaluronan; synovial joint fluid; thiol compound

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; BUCILLAMINE; CATALASE; COSMETIC; CYSTEINE; DITHIOERYTHRITOL; FREE RADICAL; GLUCURONIC ACID; GLUTATHIONE; HYALURONIC ACID; MERCAPTAMINE; N ACETYLGLUCOSAMINE; PENICILLAMINE; POLYSACCHARIDE; REACTIVE OXYGEN METABOLITE; SCAVENGER; SUPEROXIDE DISMUTASE; THIOL DERIVATIVE; WATER;

ANGIOGENESIS; ANTIOXIDANT ACTIVITY; ARTICULAR CARTILAGE; CELL ACTIVITY; DEGRADATION; DRUG DELIVERY SYSTEM; FLOW KINETICS; HOMEOSTASIS; HUMAN; JOINT; LUBRICATION; MACROMOLECULE; MOLECULAR WEIGHT; OSMOTIC PRESSURE; OXIDATIVE STRESS; PHYSICAL CHEMISTRY; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVIUM; VISCOELASTICITY;

EID: 84897925748     PISSN: 13376853     EISSN: 13379569     Source Type: Journal    
DOI: 10.2478/intox-2013-0019     Document Type: Review

References (218)

1. Abeydeera LR. (2002). In vitro production of embryos in swine. Theriogenology 57: 257-273. (Pubitemid 34000716)
2. Adams ME. (1993). Viseosupplementation: A treatment for osteoarthritis. J Rheumatol 20: Suppl. 39: 1-24.
3. Altman RD. (2000). Intra-articular sodium hyaluronate in osteoarthritis of the knee. Semin Arthritis Rheum 30: 11-18.
4. Aruoma OI, Halliwell B, Hoey BM, Butler J. (1989). The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 6: 593.
5. Ashhurst DE, Bland YS, Levick JR. (1991). An immunohistochemical study of the collagens of rabbit synovial interstitium. J Rheumatol 18: 1669-1672.
6. Athanasou NA, Quinn J. (1991). Immunocytochemical analysis of human synovial lining cells: phenotypic relation to other marrow derived cells. Ann Rheum Dis 50: 311-315.
7. Balazs EA, Denlinger JL. (1989). Clinical uses of hyaluronan. Ciba Found Symp 143: 265-280.
8. Balazs EA, Laurent TC, Jeanloz RW. (1986). Nomencla ture of hyaluronic acid. Biochemical Journal 235: 903.
9. Balazs EA. (2003). Analgesic effect of elastoviscous hyaluronan solutions and the treatment of arthritic pain. Cells Tissues Organs 174: 49-62. (Pubitemid 36677093)
10. Balazs EA, Denlinger JL. (1993). Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol 20: 3-9. (Pubitemid 23284286)
11. Banasova M, Valachova K, Juranek I, Soltes L. (2012). Effect of thiol compounds on oxidative degradation of high molar hyaluronan in vitro. Interdiscip Toxicol 5(Suppl. 1): 25-26.
12. Banasova M, Valachova K, Juranek I, Soltes L. (2013b). Aloevera and methylsulfonylmethane as dietary supplements: Their potential benefits for arthritic patients with diabetic complications. Journal of Information Intelligence and Knowledge 5: 51-68.
13. Banasova M, Valachova K, Rychly J, Priesolova E, Nagy M, Juranek I, Soltes L. (2011). Scavenging and chain breaking activity of bucillamine on free-radical mediated degradation of high molar mass hyaluronan. ChemZi 7: 205-206.
14. Baňasová M, Valachová K, Hrabárová E, Priesolová E, Nagy M, Juránek I, Šoltés L. (2011). Early stage of the acute phase of joint inflammation. In vitro testing of bucillamine and its oxidized metabolite SA981 in the function of antioxidants. 16th Interdisciplinary Czech-Slovak Toxicological Conference in Prague. Interdiscip Toxicol 4(2): 22.
15. Barrett J P, Siviero P. (2002). Retrospective study of outcomes in Hyalgan(R)-treated patients with osteoarthritis of the knee. Clin Drug Invest 22: 87-97. (Pubitemid 34158092)
16. Bergeret-Galley C, Latouche X, Illouz Y G.(2001). The value of a new filler material in corrective and cosmetic surgery: Derma Live and Derma Deep. Aesthetic Plast Surg 25: 249-255. (Pubitemid 32911429)
17. Bernatchez SF, Tabatabay C, Gurny R. (1993). Sodium hyaluronate 0.25-percent used as a vehicle increases the bioavailability of topically administered gentamicin. Graefes Arch Clin Exp Ophthalmol 231: 157-161. (Pubitemid 23088022)
18. Betts WH, Cleland LG. (1982): Effect of metal chelators and antiinflammatory drugs on the degradation of hyaluronic acid. Arthritis Rheum 25: 1469-1476. (Pubitemid 13202230)
19. Blake DR, Hall ND, Treby DA. (1981). Protection against superoxide and hydrogen peroxide in synovial fluid from rheumatoid patients. Clin Sci 61: 483-486. (Pubitemid 12243016)
20. Blewis ME, Nugent-Derfus GE, Schmidt TA, Schumacher BL, Sah RL. (2007). A model of synovial fluid lubricant composition in normal and injured. European cells and materials 13: 26-39.
21. Bothner H, Wik O. (1987). Rheology of hyaluronate. Acta Otolaryngol Suppl 442: 25-30. (Pubitemid 18018238)
22. Brandt K. (1970). Modification of chemotaxis by synovial fluid hyaluronate. Arthritis Rheum 13: 308-309.
23. Brown MB, Jones SA. (2005). Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol 19: 308-318. (Pubitemid 40691707)
24. Brown TJ, Laurent UBG, Fraser JRE. (1991). Turnover of hyaluronan in synovial joints: elimination of labelled hyaluronan from the knee joints of the rabbit. Exp Physiol 76: 125-34.
25. Bucolo C, Mangiafico P. (1999). Pharmacological profile of a new topical pilocarpine formulation. J Ocul Pharmacol Ther 15: 567-573.
26. Bucolo C, Spadaro A, Mangiafico S. (1998). Pharmacological evaluation of a new timolol/pilocarpine formulation. Ophthalmic Res 30: 101-106. (Pubitemid 28080580)
27. Camber O, Edman P, Gurny R. (1987). Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. Curr Eye Res 6: 779-784. (Pubitemid 17109903)
28. Camber O, Edman P. (1989). Sodium hyaluronate as an ophthalmic vehicle-some factors governing its effect on the ocular absorption of pilocarpine. Curr Eye Res 8: 563-567. (Pubitemid 19160718)
29. Cantor JO, Cerreta JM, Armand G, Turino GM. (1998). Aerosolized hyaluronic acid decreases alveolar injury induced by human neutrophil elastase. Proc Soc Exp Biol Med 217: 471-475.
30. Chabrecek P, Soltes L, Kallay Z, Fugedi A. (1990). Isolation and characterization of high molecular weight (3H) hyaluronic acid. J Label Compd Radiopharm 28: 1121-1125. (Pubitemid 20346988)
31. Chabrecek P, Soltes L, Kallay Z, Novak I. (1990). Gel permeation chromatographic characterization of sodium hyaluronate and its reactions prepared by ultrasonic degradation. Chromatographia 30: 201-204.
32. Chen FH, Rousche KT, Tuan RS. (2006). Technology Insight: adult stem cells in cartilage regeneration and tissue engineering. Nat Clin Pract Rheumatol 2(7): 373-82.
33. Coleman P, Kavanagh E, Mason RM, Levick JR, Ashhurst DE. (1998). The proteoglycans and glycosaminoglycan chains of rabbit synovium. Histochem J 30: 519-524. (Pubitemid 28341688)
34. Comper WD, Laurent TC. (1978). Physiological function of connective tissue polysaccharidcs. Physiol Rev 58: 255-315. (Pubitemid 9081040)
35. Cowman MK, Matsuoka S. (2005). Experimental ap proaches to hyaluronan structure. Carbohydrate Re search 340: 791-809.
36. Dahl LB, Dahl IM, Engstrom-Laurent A, Granath K. (1985). Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis 44: 817-822. (Pubitemid 16222234)
37. Dobbie JW, Hind C, Meijers P, Bodart C, Tasiaux N, Perret J, Anderson JD. (1995). Lamellar body secretion: ultrastructural analysis of an unexplored function of synoviocytes. Br J Rheumatol 34: 13-23.
38. Dougados M. (2000). Sodium hyaluronate therapy in osteoarthritis: arguments for a potential beneficial structural effect. Semin Arthritis Rheum 30: 19-25.
39. Dráfi F, Valachová K, Hrabárová E, Juránek I, Bauerová K, Šoltés L. (2010). Study of methotrexate and β-alanyl-L-histidine in comparison with L-glutathione on high-molar-mass hyaluronan degradation induced by ascorbate plus Cu (II) ions via rotational viscometry. 60th Pharmacological Days in Hradec Králové. Acta Medica 53(3): 170.
40. Drobnik J. (1991). Hyaluronan in drug delivery. Adv Drug Dev Rev 7: 295-308.
41. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. (1998). Injectable hyaluronic acid gel for soft tissue augmentation-a clinical and histological study. Dermatol Surg 24: 1317-1325. (Pubitemid 29018221)
42. Edwards JCW, Wilkinson LS, Jones HM. (1994). The formation of human synovial cavities: a possible role for hyaluronan and CD44 in altered interzone cohesion. J Anat 185: 355-67. (Pubitemid 24302068)
43. Edwards JCW (1995). Consensus statement. Second international meeting on synovium. Cell biology, physiology and pathology. Ann Rheum Dis 54: 389-91.
44. Eliaz RE, Szoka FC. (2001). Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res 61: 2592-2601. (Pubitemid 32685844)
45. Figueiredo F, Jones GM, Thouas GA, Trounson AO. (2002). The effect of extracellular matrix molecules on mouse preimplantation embryo development in vitro. Reprod Fertil Dev 14: 443-451. (Pubitemid 36231127)
46. Fisher AE, Naughton ODP. (2005). Therapeutic chelators for the twenty first century: new treatments for iron and copper mediated inflammatory and neurological disorders. Curr Drug Delivery 2: 261-268. (Pubitemid 40943998)
47. Fraser JRE, Foo WK, Maritz JS. (1972). Viscous interactions of hyaluronic acid with some proteins and neutral saccharides. Ann Rheum Dis 31: 513-20.
48. Fraser JRE, Kimpton WG, Pierscionek BK, Cahill RNP. (1993). The kinetics of hyaluronan in normal and acutely inflamed synovial joints-observations with experimental arthritis in sheep. Semin Arthritis Rheum 22: 9-17. (Pubitemid 23176279)
49. Furnus CC, de Matos DG, Martinez AG. (1998). Effect of hyaluronic acid on development of in vitro produced bovine embryos. Theriogenology 49: 1489-99. (Pubitemid 28285791)
50. Gandolfi SA, Massari A, Orsoni JG. (1992). Low-molecular-weight sodium hyaluronate in the treatment of bacterial corneal ulcers. Graefes Arch Clin Exp Ophthalmol 230: 20-23.
51. Gardner DK, Lane M, Stevens J, Schoolcraft WB. (2003). Changing the start temperature and cooling rate in a slow-freezing protocol increases human blastocyst viability. Fertil Steril 79: 407-410. (Pubitemid 36144067)
52. Gardner DK, Rodriegez-Martinez H, Lane M. (1999). Fetal development after transfer is increased by replacing protein with the glycosaminoglycan hyaluronan for mouse embryo culture and transfer. Hum Reprod 14: 2575-2580. (Pubitemid 29473932)
53. Ghosh P, Guidolin D. (2002). Potential mechanism of action of intraarticular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum 32: 10-37. (Pubitemid 35001162)
54. Ghosh S, Jassal M. (2002). Use of polysaccharide fibres for modem wound dressings. Indian J Fibre Textile Res 27: 434-450. (Pubitemid 36196081)
55. Gibbs DA, Merrill EW, Smith KA, Balazs EA. (1968). Rheology of hyaluronic acid. Biopolymers 6: 777-91.
56. Glogau RG. (2000). The risk of progression to invasive disease. J Am Acad Dermatol 42: S23-S24. (Pubitemid 30481727)
57. Grootveld M, Henderson EB, Farrell A, Blake DR, Parkes HG, Haycock P. (1991). Oxidative damage to hyaluronate and glucose in synovial fluid during exercise of the inflamed rheumatoid joint. Detection of abnormal low-molecular-mass metabolites by proton-N.M.R. spectroscopy. Biochem J 273: 459-467.
58. Guidolin DD, Ronchetti IP, Lini E. (2001). Morphological analysis of articular cartilage biopsies from a randomized. clinical study comparing the effects of 500-730 kDa sodium hyaluronate Hyalgan(R) and methylprednisolone acetate on primary osteoarthritis of the knee. Osteoarthritis Cartilage 9: 371-381. (Pubitemid 32454781)
59. Gurny R, Ibrahim H, Aebi A. (1987). Design and evaluation of controlled release systems for the eye. J Control Release 6: 367-373. (Pubitemid 18019091)
60. Haddad JJ, Harb HL. (2005). L-gamma-Glutamyl-L-cysteinyl-glycine (glutathione; GSH) and GSH-related enzymes in the regulation of pro-and anti-inflammatory cytokines: a signaling transcriptional scenario for redox(y) immunologic sensor(s). Mol Immunol 42: 987-1014.
61. Hamburger MI, Lakhanpal S, Mooar PA, Oster D. (2003). Intra-articular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum 32: 296-309. (Pubitemid 36459279)
62. Haubeck HD, Kock R, Fischer DC, van de Leur E, Hoffmeister K, Greiling H. (1995). Transforming growth factor ß1, a major stimulator of hyaluronan synthesis in human synovial lining cells. Arthritis Rheum 38: 669-677.
63. Herrero-Vanrell R, Fernandez-Carballido A, Frutos G, Cadorniga R. (2000). Enhancement of the mydriatic response to tropicamide by bioadhesive polymers. J Ocul Pharmacol Ther 16: 419-428.
64. Hills BA, Crawford RW. (2003) Normal and prosthetic synovial joints are lubricated by surface-active phospholipid: a hypothesis. J Arthroplasty 18: 499-505. (Pubitemid 36750123)
65. Hlavacek M. (1993). The role of synovial fluid filtration by cartilage in lubrication of synovial joints. J Biomech 26(10): 1145-50. (Pubitemid 23284832)
66. Hochberg MC. (2000). Role of intra-articular hyaluronic acid preparations in medical management of osteoarthritis of the knee. Semin Arthritis Rheum 30: 2-10.
67. Hrabarova E, Valachova K, Rapta P, Soltes L. (2010). An alternative standard for trolox-equivalent antioxidant-capacity estimation based on thiol antioxidants. Comparative 2,2'-azinobis[3-ethylbenzothiazoline-6-sulfonic acid] decolorization and rotational viscometry study regarding hyaluronan degradation. Chemistry & Biodiversity 7(9): 2191-2200.
68. Hrabarova E, Valachova K, Rychly J, Rapta P, Sasinkova V, Malikova M, Soltes L. (2009). High-molar-mass hyaluronan degradation by Weissberger's system: Pro-and anti-oxidative effects of some thiol compounds. Polymer Degradation and Stability 94: 1867-1875.
69. Hrabarova E, Valachova K, Juranek I, Soltes L. (2012). Free-radical degradation of high-molar-mass hyaluronan induced by ascorbate plus cupric ions: evaluation of antioxidative effect of cysteine-derived compounds. Chemistry & Biodiversity 9: 309-317.
70. Hrabarova E, Gemeiner P, Soltes L. (2007). Peroxynitrite: In vivo and in vitro synthesis and oxidant degradative action on biological systems regarding biomolecular injury and inflammatory processes. Chem Pap 61: 417-437.
71. Hrabárová E, Valachová K, Juránek I, Šoltés L. (2011). Free-radical degradation of high-molar-mass hyaluronan induced by ascorbate plus cupric ions. Antioxidative properties of the Piešt'any-spa curative waters from healing peloid and maturation pool. In: "Kinetics, Catalysis and Mechanism of Chemical Reactions" G. E. Zaikov (eds), Nova Science Publishers, New York, pp. 29-36.
72. Hrabárová E, Valachová K, Rychlý J, Rapta P, Sasinková V, Gemeiner P, Šoltés L. (2009). High-molar-mass hyaluronan degradation by the Weissbergeŕs system: pro-and antioxidative effects of some thiol compounds. Polym Degrad Stab 94: 1867-1875.
73. Hultberg M, Hultberg B. (2006). The effect of different antioxidants on glutathione turnover in human cell lines and their interaction with hydrogen peroxide. Chem Biol Interact 163(3): 192-198. (Pubitemid 44572224)
74. Hutadilok N. Ghosh P, Brooks PM. (1988). Binding of haptoglobin. inter-α-trypsin inhibitor, and l proteinase inhibitor to synovial fluid hyaluronate and the influence of these proteins on its degradation byoxygen derived free radicals. Ann Rheum Dis 47: 377-85.
75. Inoue M, Katakami C. (1993). The effect of hyaluronic-acid on corneal epithelial-cell proliferation. Invest Ophthalmol Vis Sci 34: 2313-2315. (Pubitemid 23191260)
76. Itano N, Kimata K. (2002). Mammalian hyaluronan synthases. IUBMB Life 54: 195-199. (Pubitemid 36008328)
77. Jaakma U, Zhang B R, Larsson B. (1997). Effects of sperm treatments on the in vitro development of bovine oocytes in semidefined and defined media. Theriogenology 48: 711-720. (Pubitemid 28135490)
78. Jang G, Lee BC, Kang SK, Hwang WS. (2003). Effect of glycosaminoglycans on the preimplantation development of embryos derived from in vitro fertilization and somatic cell nuclear transfer. Reprod Fertil Dev 15: 179-185. (Pubitemid 37080715)
79. Jarvinen K, Jarvinen T, Urtti A. (1995). Ocular absorption following topical delivery. Adv Drug Dev Rev 16: 3-19.
80. Jay GD, Britt DE, Cha DJ. (2000). Lubricin is a product of megakaryocyte stimulating factor gene expression by human synovial fibroblasts. J Rheumatol 27: 594-600. (Pubitemid 30151333)
81. Joly T, Nibart M, Thibier M. (1992). Hyaluronic-acid as a substitute for proteins in the deep-freezing of embryos from mice and sheep-an in vitro investigation. Theriogenology 37: 473-480.
82. Juranek I, Soltes L. (2012). Reactive oxygen species in joint physiology: Possible mechanism of maintaining hypoxia to protect chondrocytes from oxygen excess via synovial fluid hyaluronan peroxidation. In: "Kinetics, Catalysis and Mechanism of Chemical Reactions: From Pure to Applied Science. Volume 2-Tomorrow and Perspectives" R.M. Islamova, S.V. Kolesov, G.E. Zaikov (eds), Nova Science Publishers, New York pp. 1-10
83. Kano K, Miyano T, Kato S. (1998). Effects of glycosaminoglycans on the development of in vitro matured and fertilized porcine oocytes to the blastocyst stage in vitro. Biol Reprod 58: 1226-1232. (Pubitemid 28217247)
84. Kelly MA, Goldberg VM, Healy WL. (2003). Osteoarthritis and beyond: a consensus on the past, present, and future of hyaluronans in orthopedics. Orthopedics 26: 1064-1079. (Pubitemid 37304421)
85. Kemmann E. (1998). Creutzfeldt-Jakob disease (CJD) and assisted reproductive technology (ART)-quantification of risks as part of informed consent. Hum Reprod 13: 1777.
86. Kessler A, Biasibetti M, da Silva Melo DA, Wajner M, Dutra-Filho CS, de Souza Wyse AT, Wannmacher CMD. (2008). Antioxidant effect of cysteamine in brain cortex of young rats. Neurochem Res 33: 737-44. (Pubitemid 351423138)
87. Kim A, Checkla DM, Dehazya P, Chen WL. (2003). Characterization of DNAhyaluronan matrix for sustained gene transfer. J Control Release 90: 81-95. (Pubitemid 36588881)
88. Kirwan J. (2001). Is there a place for intra-articular hyaluronate in osteoarthritis of the knee? Knee 8: 93-101. (Pubitemid 32405246)
89. Knight AD, Levick JR. (1984). Morphometry of the ultrastructure of the bloodjoint barrier in the rabbit knee. Q J Exp Physiol 69: 271-288. (Pubitemid 14138557)
90. Kogan G. (2010). Hyaluronan-A High Molar mass messenger reporting on the status of synovial joints: part 1. Physiological status In: New Steps in Chemical and Biochemical Physics. ISBN: 97 8-1-61668-923-0. pp. 121-133.
91. Kogan G, Soltes L, Stern R, Mendichi R. (2007a). Hyaluronic acid: A biopolymer with versatile physico-chemical and biological properties. Chapter 31-in: Handbook of Polymer Research: Monomers, Oligomers, Polymers and Composites. Pethrick R. A, Ballada A, Zaikov G. E. (eds.), Nova Science Publishers, New York, pp. 393-439.
92. Kogan G, Soltes L, Stern R, Gemeiner P. (2007). Hyaluronic acid: A natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol Lett 29: 17-25. (Pubitemid 44950153)
93. Kreil G. (1995). Hyaluronidases-A group of neglected enzymes. Protein Sciences 4: 1666-1669.
94. Lane M, Maybach JM, Hooper K. (2003). Cryo-survival and development of bovine blastocysts are enhanced by culture with recombinant albumin and hyaluronan. Mol Reprod Dev 64: 70-78. (Pubitemid 35398489)
95. Langer K, Mutschler E, Lambrecht G. (1997). Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery-Part III. Evaluation as drug delivery system for ophthalmic applications. Int J Pharm 158: 219-231. (Pubitemid 28012909)
96. Lath D, Csomorova K, Kollarikova G, Stankovska M, Soltes L. (2005). Molar mass-intrinsic viscosity relationship of high-molar-mass yaluronans: Involvement of shear rate. Chem Pap 59: 291-293. (Pubitemid 43036096)
97. Laurent TC, Laurent UBG, Fraser JRE. (1996). The structure and function of hyaluronan: An over view. Immunology and Cell Biology 74: A1-A7.
98. Laurent TC. (1989). The biology of hyaluronan. In: Ciba Foundation Symposium. John Wiley and Sons, New York. 143: 1-298.
99. Laurent TC, Fraser JRE. (1992). Hyaluronan. FASEB J 6: 2397-2404.
100. Laurent TC. Laurent UBG, Fraser JRE. (1995). Functions of hyaluronan. Ann Rheum Dis 54: 429-32.
101. Laurent TC, Ryan M, Pictruszkiewicz A. (1960). Fractionation of hyaluronic acid. The polydispersity of hyaluronic acid from the vitreous body. Biochim Biophys Acta 42: 476-85.
102. Levick JR. (1994). An analysis of the interaction between interstitial plasma protein, interstitial flow, and fenestral filtration and its application to synovium. Microvasc Res 47: 90-125. (Pubitemid 24194858)
103. Leyden J, Narins RS, Brandt F. (2003). A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 29: 588-595. (Pubitemid 36702442)
104. Lim ST, Forbes B, Berry DJ, Martin GP, Brown MB. (2002). In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits. Int J Pharm 231: 73-82. (Pubitemid 33086821)
105. Luo Y, Prestwich GD. (1999). Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem 10: 755-763. (Pubitemid 29456361)
106. Luo Y, Ziebell MR, Prestwich GD. (2000). A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 1: 208-218.
107. Maheu E, Ayral X, Dougados M. (2002). A hyaluronan preparation (500-730 kDa) in the treatment of osteoarthritis: a review of clinical trials with Hyalgan(R). Int J Clin Pract 56: 804-813. (Pubitemid 36104549)
108. Manuskiatti W, Maibach HI. (1996). Hyaluronic acid and skin: wound healing and aging. Int J Dermatol 35: 539-544. (Pubitemid 26261919)
109. Mazzucco D, Scott R, Spector M. (2004). Composition of joint fluid in patients undergoing total knee replacement and revision arthroplasty: correlation with flow properties. Biomaterials 25: 4433-4445. (Pubitemid 38388603)
110. McCord JM. (1974). Free radicals and inflammation: protection of synovial fluid by superoxide dismutase. Science 185: 529-531.
111. McDonald JN, Levick JR. (1988). Morphology of surface synoviocytes in situ at normal and raised joint pressure, studied by scanning electron microscopy. Ann Rheum Dis 47: 232-240. (Pubitemid 18081615)
112. McDonald JN, Leviek JR. (1995). Effect of intra-articular hyaluronan on pressure-flow relation across synovium in anaesthetized rabbits. J Physiol 485(Pt.1): 179-93.
113. Mendichi R, Soltes L. (2002). Hyaluronan molecular weight and polydispersity in some commercial intra-articular injectable preparations and in synovial fluid Inflamm Res 51: 115-116. (Pubitemid 34297848)
114. Meyer K, Palmer JW. (1934). The polysaccharide of the vitreous humor. Journal of Biology and Chemistry 107: 629-634.
115. Miltner O, Schneider U, Siebert CH. (2002). Efficacy of intraarticular hyaluronic acid in patients with osteoarthritis-a prospective clinical trial. Osteoarthritis Cartilage 10: 680-686. (Pubitemid 34993956)
116. Miyano T, Hirooka RE, Kano K. (1994). Effects of hyaluronic-acid on the development of 1-cell and 2-cell porcine embryos to the blastocyst stage invitro. Theriogenology 41: 1299-1305.
117. Miyazaki M, Sato S, Yamaguchi T. (1983). Analgesic and antiinflammatory action of hyaluronic sodium, Japan Pharmacological Conference. Tokyo, April 4, 1983.
118. Miyazaki T, Miyauchi S, Nakamura T. (1996). The effect of sodium hyaluronate on the growth of rabbit cornea epithelial cells in vitro. J Ocul Pharmacol Ther 12: 409-415. (Pubitemid 26405745)
119. Momberger TS, Levick JR, Mason RM. (2005). Hyaluronan secretion by synoviocytes is mechanosensitive. Matrix Biol 24: 510-519. (Pubitemid 41713146)
120. Moreira CA, Armstrong DK, Jelliffe RW. (1991). Sodium hyaluronate as a carrier for intravitreal gentamicin-an experimental study. Acta Ophthalmol (Copenh) 69: 45-49.
121. Moreira CA, Moreira AT, Armstrong DK. (1991). in vitro and In vivo studies with sodium hyaluronate as a carrier for intraocular gentamicin. Acta Ophthalmol (Copenh) 69: 50-56.
122. Morimoto K, Metsugi K, Katsumata H. (2001). Effects of lowviscosity sodium hyaluronate preparation on the pulmonary absorption of rh-insulin in rats. Drug Dev Ind Pharm 27: 365-371. (Pubitemid 32531604)
123. Morimoto K, Yamaguchi H, Iwakura Y. (1991). Effects of viscous hyaluronatesodium solutions on the nasal absorption of vasopressin and an analog. Pharmacol Res 8: 471-474.
124. Morris ER, Rees DA, Welsh EJ. (1980). Conformation and dynamic interactions in hyaluronate solutions. J Mol Biol 138: 383-400.
125. Myint P. (1987). The reactivity of various free radicals with hyaluronic acid steady-state and pulse radiolysis studies. Biochim Biophys-Aeta 925: 194-202.
126. Necas J, Bartosikova L, Brauner P, Kolar J. (2008). Hyaluronic acid (hyaluronan): a review. Veterinarni Medicina 53(8): 397-411.
127. Niwa Y, Sakane T, Shingu M, Yokoyama MM. (1983). Effect of stimulated neutrophils from the synovial fluid of patients with rheumatoid arthritis on lymphocytes: a possible role of increased oxygen radicals generated by the neutrophils. J Clin Immunol 3: 228-240. (Pubitemid 13015196)
128. Noble PW. (2002). Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol 21: 25-29. (Pubitemid 34100819)
129. Oates KMN, Krause WE, Colby RH. (2002). Using rheology to probe the mechanism of joint lubrication: polyelectrolyte/protein interactions in synovial fluid. Mat Res Soc Syrnp Proc 711: 53-58.
130. Ogston AG, Stanier JE. (1953). The physiological function of hyaluronic acid in synovial fluid viscous, elastic and lubricant properties. J Physiol 199: 244-52.
131. Ortonne JP. (1996). A controlled study of the activity of hyaluronic acid in the treatment of venous leg ulcers. J Dermatol Treatment 7: 75-81. (Pubitemid 26235527)
132. Orvisky E, Soltes L, Chabrecek P, Novak I, Kery V, Stancikova M, Vins I. (1992). The determination of hyaluronan molecular weight distribution by means of high perfeormance size exclusion chromatography. J Liq Chromatogr 15: 3203-3218. (Pubitemid 23037849)
133. Parsons BJ, Al-Assaf S, Navaratnam S, Phillips GO. (2002). Comparison of the reactivity of different oxidative species (ROS) towards hyaluronan, in: Kennedy JF, Phillips GO, Williams PA, Hascall VC (Eds.), Hyaluronan: Chemical, Biochemical and Biological Aspects, Woodhead, Publishing Ltd, Cambridge, MA, pp. 141-150.
134. Peer D, Florentin A, Margalit R. (2003). Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. Biochim Biophys Acta-Biomembranes 1612: 76-82. (Pubitemid 36555689)
135. Peer D, Margalit R. (2000). Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes. Arch Biochem Biophys 383: 185-190.
136. Poli A, Mason RM, Levick JR. (2004). Effects of Arg-Gly-Asp sequence peptide and hyperosmolarity on the permeability of interstitial matrix and fenestrated endothelium in joints. Microcirculation 11: 463-476. (Pubitemid 39618623)
137. Praest BM, Greiling H, Kock R. (1997). Effects of oxygen-derived free radicals on the molecular weight and the polydispersity of hyaluronan solutions. Carbohydr Res 303 :153-157 . (Pubitemid 27425184)
138. Price FM, Levick JR, Mason RM. (1996). Glycosaminoglycan concentration in synovium and other tissues of rabbit knee in relation to synovial hydraulic resistance. J Physiol (Lond) 495: 803-820. (Pubitemid 26329123)
139. Prisell PT, Camber O, Hiselius J, Norstedt G. (1992). Evaluation of hyaluronan as a vehicle for peptide growth factors. Int J Pharm 85: 51-56.
140. Radin EL, Swann DA, Weisser PA. (1970). Separation of a hyaluronate-frec lubricating fraction from synovial fluid. Nature 228: 377-8.
141. Rapta P, Valachova K, Gemeiner P, Soltes L. (2009). High-molar-mass hyaluronan behavior during testing its radical scavenging capacity in organic and aqueous media: Effects of the presence of Manganese (II) ions. Chem Biodivers 6: 162-169.
142. Rapta P, Valachová K, Gemeiner P, Šoltés L. (2009). High-molar-mass hyaluronan behavior during testing its antioxidant properties in organic and aqueous media: effects of the presence of Mn(II) ions. Chem Biodivers 6: 162-169.
143. Rapta P, Valachová K, Zalibera M, Šnirc V, Šoltés L. (2010). Hyaluronan degradation by reactive oxygen species: scavenging eggect of the hexapyridoindole stobadine and two of its derivatives. In Monomers, Oligomers, Polymers, Composites, and Nanocomposites, Ed: R. A. Pethrick P. Petkov, A. Zlatarov G. E. Zaikov, S. K. Rakovsky, Nova Science Publishers, N.Y, Chapter 7, pp. 113-126.
144. Rees MD, Kennett EC, Whitelock JM, Davies MJ. (2008). Oxidative damage to extracellular matrix and its role in human pathologies. Free Radical Biol. Med 44: 1973-2001.
145. Revell PA. (1989). Synovial lining cells. Rheumatol Int 9: 49-51. (Pubitemid 19218865)
146. Risberg B. (1997). Adhesions: preventive strategies. Eur J Surg 163: 32-39. (Pubitemid 27115968)
147. Rittig M, Tittor F, Lutjen-Drecoll E, Mollenhauer J, Rauterberg J. (1992). Immunohistochemical study of extracellular material in the aged human synovial membrane. Mech Ageing Dev 64: 219-234.
148. Rychly J, Soltes L, Stankovska M, Janigova I, Csomorova K, Sasinkova V, Kogan G, Gemeiner P. (2006). Unexplored capabilities of chemiluminescence and thermoanalytical methods in characterization of intact and degraded hyaluronans. Polym Degrad Stab 91(12): 3174-3184. (Pubitemid 44894282)
149. Saettone MF, Giannaccini B, Chetoni P, et al. (1991). Evaluation of highmolecular-weight and low-molecular-weight fractions of sodium hyaluronate and an ionic complex as adjuvants for topical ophthalmic vehicles containing pilocarpine. Int J Pharm 72: 131-139.
150. Saettone MF, Monti D, Torracca MT, Chetoni P. (1994). Mucoadhesive ophthalmic vehicles-evaluation polymeric low-viscosity formulations. J Ocul Pharmacol 10: 83-92. (Pubitemid 24119432)
151. Sakurai K, Miyazaki K, Kodera Y. (1997). Anti-inflammatory activity of superoxide dismutase conjugated with sodium hyaluronate. Glycoconj J 14: 723-728. (Pubitemid 27400103)
152. Sasaki H, Yamamura K, Nishida K. (1996). Delivery of drugs to the eye by topical application. Prog Retinal Eye Res 15: 583-620. (Pubitemid 26329186)
153. Sattar A, Kumar S, West DC. (1992). Does hyaluronan have a role in endothelial cell proliferation of the synovium. Semin. Arthritis Rheum 22: 37-43.
154. Schartz RA. (1997). The actinic keratoses. A perspective and update. Dermatol Surg 23: 1009-1019.
155. Schiller J, Volpi N, Hrabarova E, Soltes L. (2011). Hyaluronic acid: a natural biopolymer In: "Handbook of Biopolymers and Their Applications" S. Kalia and L. Averous (eds), Wiley & Scrivener Publishing, USA pp. 3-34.
156. Schmid T, Lindley K, Su J, Soloveychik V, Block J, Kuettner K, Schumacher B. (2001a). Superficial zone protein (SZP) is an abundant glycoprotein in human synovial fluid and serum. Trans Orthop Res Soc 26: 82.
157. Schmid T, Soloveychik V, Kuettner K, Schumacher B. (2001b). Superficial zone protein (SZP) from human cartilage has lubrication activity. Trans Orthop Res Soc 26: 178.
158. Schumacher BL, Block JA, Schmid TM, Aydelotte MB, Kuettner KE. (1994). A novel proteoglycan synthesized and secreted by chondrocytes of the superficial zone of articular cartilage. Arch Biochem Biophys 311: 144-152. (Pubitemid 24190113)
159. Schumacher BL, Hughes CE, Kuettner KE, Caterson B, Aydelotte MB. (1999). Immunodetection and partial c DNA sequence of the proteoglycan, superficial zone protein, synthesized by cells lining synovial joints. J Orthop Res 17: 110-120. (Pubitemid 29096013)
160. Schumacher BL, Schmidt TA, Voegtline MS, Chen AC, Sah RL. (2005). Proteoglycan 4 (PRG4) synthesis and immunolocalization in bovine meniscus. J Orthop Res 23: 562-568. (Pubitemid 40631327)
161. Schwarz IM, Hills BA. (1996). Synovial surfactant: lamellar bodies in type B synoviocytes and proteolipid in synovial fluid and the articular lining. Br J Rheumatol 35: 821-827.
162. Schwarz IM, Hills BA. (1998). Surface-active phospholipids as the lubricating component of lubricin. Br J Rheumatol 37: 21-26.
163. Scott DL, Shipley M, Dawson A, Edwards S, Symmons DP, Woolf AD. (1998). The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness. Br J Rheumatol 37: 546-554.
164. Scott JE, Cummings C, Brass A, Chen Y. (1991). Secondary and tertiary structures of hyaluronan in aqueous solution, investigated by rotary shadowingelectron microscopy and computer simulation. Biochem J 274: 600-705.
165. Servaty R, Schiller J, Binder H, Arnold K. (2000). Hydration of polymeric components of the cartilage-An infrared spectroscopic study on hyaluronic acid and chondroitin sulfate. Int J Biol Macromol 28: 123-129.
166. 4OH solution. Carbohydr Polym 41: 9-14. (Pubitemid 30509278)
167. Simon A, Safran A, Revel A. (2003). Hyaluronic acid can successfully replace albumin as the sole macromolecule in a human embryo transfer medium. Fertil Steril 79: 1434-1438. (Pubitemid 36687893)
168. Soldati D, Rahm F, Pasche P. (1999). Mucosal wound healing after nasal surgery. A controlled clinical trial on the efficacy of hyaluronic acid containing cream. Drugs Exp Clin Res 25: 253-261. (Pubitemid 30093773)
169. Soloveva ME, Solovev VV, Faskhutdinova AA, Kudryavtsev AA, Akatov VS. (2007). Prooxidant and cytotoxic action of N-acetylcysteine and glutathione in combinations with vitamin B12b. Cell Tissue Biol 1: 40-49.
170. Soltes L, Kogan G. (2009). Impact of transition metals in the free-radical degradation of hyaluronan biopolymer In: "Kinetics & Thermodynamics for Chemistry & Biochemistry: Vol. 2" E. M. Pearce, G. E. Zaikov, G. Kirshenbaum (eds), Nova Science Publishers, New York (181-199).
171. Soltes L, Mendichi R, Kogan G, Mach M. (2004). Associating Hyaluronan Derivatives: A Novel Horizon in Viscosupplementation of Osteoarthritic Joints. Chem Biodivers 1: 468-472.
172. Soltes L, Brezova V, Stankovska M, Kogan G, Gemeiner P. (2006a). Degradation of high-molecular-weight hyaluronan by hydrogen peroxide in the presence of cupric ions. Carbohydr Res 341: 639-644.
173. Soltes L, Mendichi R, Kogan G, Schiller J, Stankovska M, Arnhold J. (2006b) Degradative action of reactive oxygen species on hyaluronan. Biomacromolecules 7: 659-668.
174. Soltes L, Stankovska M, Brezova V, Schiller J, Arnhold J, Kogan G, Gemeiner P. (2006c). Hyaluronan degradation by copper (II) chloride and ascorbate: rotational viscometric, EPR spin-trapping, and MALDI-TOF mass spectrometric investigations Carbohydr Res 341: 2826-2834. (Pubitemid 44692666)
175. Soltes L, Stankovska M, Kogan G, Germeiner P, Stern R. (2005). Contribution of oxidative reductive reations to high molecular weight hyaluronan catabolism. Chem Biodivers 2: 1242-1245.
176. Soltes L, Valachova K, Mendichi R, Kogan G, Arnhold J, Gemeiner P. (2007). Solution properties of high-molar-mass hyaluronans: the biopolymer degradation by ascorbate. Carbohydr Res 342: 1071-1077. (Pubitemid 46551992)
177. Soltes L. (2010). Hyaluronan-A High-Molar-Mass Messenger Reporting on the Status of Synovial Joints: Part II. Pathophysiological Status In: "New Steps in Chemical and Biochemical Physics. Pure and Applied Science" E. M. Pearce, G. Kirshenbaum, G. E. Zaikov (eds), Nova Science Publishers, New York pp. 137-152.
178. Stankovska M, Arnhold J, Rychly J, Spalteholz H, Gemeiner P, Soltes L. (2007). in vitro screening of the action of non-steroidal anti-inflammatory drugs on hypochlorous acid-induced hyaluronan degradation. Polym Degrad Stabil 92: 644-652. (Pubitemid 46509651)
179. Stankovska M, Soltes L, Vikartovska A, Mendichi r, Lath D, Molnarova M, Gemeiner P. (2004). Study of hyaluronan degradation by means of rotational Viscometry: Contribution of the material of viscometer. Chem Pap 58: 348-352. (Pubitemid 40208215)
180. Stankovska M, Hrabarova E, Valachova K, Molnarova M, Gemeiner P, Soltes L. (2006). The degradative action of peroxynitrite on high-molecular-weight hyaluronan . Neuroendocrinol Lett 27(Suppl. 2): 31-34. (Pubitemid 46534332)
181. Stankovska M, Soltes L, Vikartovska A, Gemeiner P, Kogan G, Bakos D. (2005). Degradation of high-molecular-weight hyaluronan: a rotational viscometry study. Biologia 60(Suppl. 17): 149-152. (Pubitemid 44804888)
182. Stern R, Kogan G, Jedrzejas M. J, Soltes L. (2007). The many ways to cleave hyaluronan. Biotechnol Adv 25: 537-557. (Pubitemid 47464847)
183. Stiebel-Kalish H, Gaton DD, Weinberger D. (1998). A comparison of the effect of hyaluronic acid versus gentamicin on corneal epithelial healing. Eye 12: 829-833. (Pubitemid 28482809)
184. Suchanek E, Simunic V, Juretic D, Grizelj V. (1994). Follicular-fluid contents of hyaluronic-acid, follicle-stimulating-hormone and steroids relative to the success of in-vitro fertilization of human oocytes. Fertil Steril 62: 347-352. (Pubitemid 24233287)
185. Surendrakumar K, Martyn GP, Hodgers ECM. (2003). Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J Control Release 91: 385-394. (Pubitemid 36980658)
186. Surini S, Akiyama H, Morishita M. (2003). Polyion complex of chitosan and sodium hyaluronate as an implant device for insulin delivery. STP Pharm Sci 13: 265-268. (Pubitemid 37337353)
187. Surovcikova L, Valachova K, Banasova M, Snirc V, Priesolova E, Nagy M, Juranek I, Soltes L. (2012). Free-radical degradation of high-molar-mass hyaluronan induced by ascorbate plus cupric ions: Testing of stobadine and its two derivatives in function as antioxidants. General Physiol Biophys 31: 57-64.
188. Swann DA, Silver FH, Slayter HS, Stafford W, Shore E. (1985). The molecular structure and lubricating activity of lubricin isolated from bovine and human synovial fluids. Biochem J 225: 195-201. (Pubitemid 15151970)
189. Takayama K, Hirata M, Machida Y. (1990). Effect of interpolymer complex-formation on bioadhesive property and drug release phenomenon of compressed tablet consisting of chitosan and sodium hyaluronate. Chem Pharmaceut Bull 38: 1993-1997. (Pubitemid 20277419)
190. Tani E, Katakami C, Negi A (2002). Effects of various eye drops on corneal wound healing after superficial keratectomy in rabbits. Jpn J Ophthalmol 46: 488-495. (Pubitemid 35380001)
191. Tascioglu F, Oner C. (2003). Efficacy of intra-articular sodium hyaluronate in the treatment of knee osteoarthritis. Clin Rheumatol 22: 112-117. (Pubitemid 36748859)
192. Thibodeau PA, Kocsis-Bedard S, Courteau J, Niyonsenga T, Paquette B. (2001). Thiols can either enhance or suppress DNA damage induction by catecholestrogens. Free Radic Biol Med 30: 62-73. (Pubitemid 32008089)
193. Turino GM, Cantor JO. (2003). Hyaluronan in respiratory injury and repair. Am J Respir Crit Care Med 167: 1169-1175. (Pubitemid 36555086)
194. Uthman I, Raynauld JP, Haraoui B. (2003). Intra-articular therapy in osteoarthritis. Postgrad Med J 79: 449-453. (Pubitemid 37152222)
195. Valachova K, Vargova A, Rapta P, Hrabarova E, Drafi F, Bauerova K, Juranek I, Soltes L. (2011). Aurothiomalate as preventive and chain-breaking antioxidant in radical degradation of high-molar-mass hyaluronan. Chemistry & Biodiversity 8: 1274-1283.
196. Valachova K, Banasova M, Machova L, Juranek I, Bezek S, Soltes L. (2013b). Antioxidant activity of various hexahydropyridoindoles. Journal of Information Intelligence and Knowledge 5: 15-32.
197. Valachova K, Hrabarova E, Priesolova E, Nagy M, Banasova M, Juranek I, Soltes L. (2011). Free-radical degradation of high-molecular-weight hyaluronan induced by ascorbate plus cupric ions. Testing of bucillamine and its SA981-metabolite as antioxidants. J Pharma & Biomedical Analysis 56: 664-670.
198. Valachová K, Hrabárová E, Dráfi F, Juránek I, Bauerová K, Priesolová E, Nagy M, Šoltés L. (2010a). Ascorbate and Cu(II) induced oxidative degradation of high-molar-mass hyaluronan. Pro-and antioxidative effects of some thiols. Neuroendocrinol Lett 31(2): 101-104.
199. Valachová K, Hrabárová E, Gemeiner P, Šoltés L. (2008). Study of pro-and anti-oxidative properties of d-penicillamine in a system comprising highmolar-mass hyaluronan, ascorbate, and cupric ions. Neuroendocrinol Lett 29: 697-701.
200. Valachová K, Hrabárová E, Juránek I, Šoltés L. (2011b). Radical degradation of high-molar-mass hyaluronan induced by Weissberger oxidative system. Testing of thiol compounds in the function of antioxidants. 16th Interdisciplinary Slovak-Czech Toxicological Conference in Prague. Interdiscip Toxicol 4(2): 65.
201. Valachová K, Kogan G, Gemeiner P, Šoltés L. (2008b). Hyaluronan degradation by ascorbate: Protective effects of manganese (II). Cellulose Chem. Technol 42(9-10): 473-483.
202. Valachová K, Kogan G, Gemeiner P, Šoltés L. (2009b). Hyaluronan degradation by ascorbate: protective effects of manganese (II) chloride. In: Progress in Chemistry and Biochemistry. Kinetics, Thermodynamics, Synthesis, Properties and Application, Nova Science Publishers, N.Y, Chapter 20, pp. 201-215.
203. Valachová K, Mendichi R, Šoltés L. (2010c). Effect of L-glutathione on high-molar-mass hyaluronan degradation by oxidative system Cu(II) plus ascorbate. In: Monomers, Oligomers, Polymers, Composites, and Nanocomposites, Ed: R. A. Pethrick P. Petkov, A. Zlatarov G. E. Zaikov, S. K. Rakovsky, Nova Science Publishers, N.Y, Chapter 6, pp. 101-111.
204. Valachová K, Rapta P, Kogan G, Hrabárová E, Gemeiner P, Šoltés L. (2009a). Degradation of high-molar-mass hyaluronan by ascorbate plus cupric ions: effects of D-penicillamine addition. Chem Biodivers 6: 389-395.
205. Valachová K, Rapta P, Slováková M, Priesolová E, Nagy M, Mislovičová D, Dráfi F, Bauerová K, Šoltés L. (2013a). Radical degradation of high-molar-mass hyaluronan induced by ascorbate plus cupric ions. Testing of arbutin in the function of antioxidant. In: Advances in Kinetics and Mechanism of Chemical Reactions, G. E. Zaikov, A. J. M. Valente, A. L. Iordanskii (eds), Apple Academic Press, Waretown, NJ, USA, pp. 1-19.
206. Valachová K, Šoltés L. (2010b). Effects of biogenic transition metal ions Zn(II) and Mn(II) on hyaluronan degradation by action of ascorbate plus Cu(II) ions. In: New Steps in Chemical and Biochemical Physics. Pure and Applied Science, Nova Science Publishers, Ed: E. M. Pearce, G. Kirshenbaum, G.E. Zaikov, Nova Science Publishers, N.Y, Chapter 10, pp. 153-160.
207. Valachová K, Vargová A, Rapta P, Hrabárová E, Dráfi F, Bauerová K, Juránek I, Šoltés L. (2011a). Aurothiomalate in function of preventive and chainbreaking antioxidant at radical degradation of high-molar-mass hyaluronan. Chem Biodivers 8: 1274-1283.
208. Vanos HC, Drogendijk AC, Fetter WPF. (1991). The influence of contamination of culture-medium with hepatitis-B virus on the outcome of in vitro fertilization pregnancies. Am J Obstet Gynecol 165: 152-159.
209. Vazquez JR, Short B, Findlow AH. (2003). Outcomes of hyaluronan therapy in diabetic foot wounds. Diabetes Res Clin Pract 59: 123-127. (Pubitemid 36135830)
210. Weigel PH, Hascall VC, Tammi M. (1997). Hyaluronan synthases. J Biol Chem 272: 13997-14000. (Pubitemid 27232793)
211. West DC, Hampson IN, Arnold F, Kumar S. (1985). Angiogenesis induced by degradation products of hyaluronic acid. Science 228: 1324-1326.
212. Wilkinson LS, Pitsillides AA, Worrall JG, Edwards JC. (1992). Light microscopic characterization of the fibroblastlike synovial intimal cell (synoviocyte). Arthritis Rheum 35: 1179-1184.
213. Worrall JG, Bayliss MT, Edwards JC. (1991). Morphological localization of hyaluronan in normal and diseased synovium. J Rheumatol 18: 1466-1472.
214. Worrall JG, Wilkinson LS, Bayliss MT, Edwards JC. (1994). Zonal distribution of chondroitin-4-sulphate/dermatan sulphate and chondroitin-6-sulphate in normal and diseased human synovium. Ann Rheum Dis 53: 35-38. (Pubitemid 24067406)
215. Yerushalmi N, Arad A, Margalit R. (1994). Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drugdelivery in wound-healing. Arch Biochem Biophys 313: 267-273. (Pubitemid 24292802)
216. Yerushalmi N, Margalit R. (1998). Hyaluronic acid-modified bioadhesive liposomes as local drug depots: effects of cellular and fluid dynamics on liposome retention at target sites. Arch Biochem Biophys 349: 21-26. (Pubitemid 28368386)
217. Yun YH, Goetz DJ, Yellen P, Chen W. (2004). Hyaluronan microspheres for sustained gene delivery and site-specific targetting. Biomaterials 25: 147-157. (Pubitemid 37324408)
218. Zhu YX, Granick S. (2003). Biolubrication: hyaluronic acid and the influence on its interfacial viscosity of an antiinflammatory drug. Macromolecules 36: 973-976.